Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy

dc.contributor.authorOlivé i Plana, Montserrat
dc.contributor.authorOdgerel, Zagaa
dc.contributor.authorMartínez, Amaia
dc.contributor.authorPoza, Juan José
dc.contributor.authorGarcía Bragado, Federico
dc.contributor.authorZabalza, Ramón J.
dc.contributor.authorJericó, Ivonne
dc.contributor.authorGonzález Mera, Laura
dc.contributor.authorShatunov, Alexey
dc.contributor.authorLee, Hee Suk
dc.contributor.authorArmstrong i Morón, Judith
dc.contributor.authorMaraví, Elías
dc.contributor.authorRamos Arroyo, María
dc.contributor.authorPascual Calvet, Jordi
dc.contributor.authorNavarro, Carmen
dc.contributor.authorParadas, Carmen
dc.contributor.authorHuerta Villanueva, Mariano
dc.contributor.authorMárquez, Fabian
dc.contributor.authorGutierrez Rivas, Eduardo
dc.contributor.authorPou, Adolf
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)
dc.contributor.authorGoldfarb, Lev G.
dc.date.accessioned2018-11-21T09:07:36Z
dc.date.available2018-11-21T09:07:36Z
dc.date.issued2011-06-14
dc.date.updated2018-11-21T09:07:36Z
dc.description.abstractMyofibrillar myopathies (MFM) are a group of disorders associated with mutations in DES, CRY A B, M YOT, ZASP, FLNC, or BAG3 genes and characterized by disintegration of myofibrils and accumulation of degradation products into intracellular inclusions. We retrospectively evaluated 53 M FM patients from 35 Spanish families. Studies included neurologic exam, muscle imaging, light and electron microscopic analysis of muscle biopsy, respiratory function testing and cardiologic work-up. Search for pathogenic mutations was accomplished by sequencing of coding regions of the six genes known to cause MFM. Mutations in M YOT were the predominant cause of MFM in Spain affecting 18 of 35 families, followed by DES in 11 and ZASP in 3; in 3 families the cause of MFM remains undetermined. Comparative analysis of DES, MYOT and ZASP associated phenotypes demonstrates substantial phenotypic distinctions that should be considered in studies of disease pathogenesis, for optimization of subtype-specific treatments and management, and directing molecular analysis. (C) 2011 Elsevier B.V. All rights reserved.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec600948
dc.identifier.issn0960-8966
dc.identifier.pmid21676617
dc.identifier.urihttps://hdl.handle.net/2445/126272
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.nmd.2011.05.002
dc.relation.ispartofNeuromuscular Disorders, 2011, vol. 21, num. 8, p. 533-542
dc.relation.urihttps://doi.org/10.1016/j.nmd.2011.05.002
dc.rights(c) Elsevier B.V., 2011
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalalties musculars
dc.subject.classificationGenètica
dc.subject.classificationMalalties hereditàries
dc.subject.classificationEspanya
dc.subject.otherMuscular Diseases
dc.subject.otherGenetics
dc.subject.otherGenetic diseases
dc.subject.otherSpain
dc.titleClinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
600948.pdf
Mida:
781.15 KB
Format:
Adobe Portable Document Format